Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Changes“
Suchtreffer
Begriffe & Kennungen
NovoNorm · 4.8 · The most frequently reported adverse reactions are changes in blood glucose levels, i.e. hypoglycaemia. The oc
Eintrag öffnenNovoNorm · 4.8 · The most frequently reported adverse reactions are changes in blood glucose levels, i.e. hypoglycaemia. The oc
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · 11 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol
Eintrag öffnenOlanzapine Glenmark Europe · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · 10 The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/L
Eintrag öffnenOlanzapine Glenmark · 4.8 · 26 The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/L
Eintrag öffnenOlanzapine Glenmark · 4.8 · 42 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol
Eintrag öffnenOlanzapine Glenmark · 4.8 · 57 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol
Eintrag öffnenOlanzapine Glenmark · 4.8 · 72 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol
Eintrag öffnenOlanzapine Glenmark · 4.8 · 87 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlazax · 4.8 · 74 The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/L
Eintrag öffnenOncaspar · 4.8 · 9 Metabolism and nutrition disorders An alteration in serum lipid levels was observed and changes in serum lip
Eintrag öffnenOrganisatorische Neuerungen
Eintrag öffnenOrgovyx · 4.5 · 13 Therapeutic dose for Abiraterone Expected: Expected: No clinically Orgovyx ↔ ↔ meaningful changes (CYP3A4 i
Eintrag öffnenOrgovyx · 4.8 · Changes in laboratory parameters Changes in laboratory values observed during up to 1 year of treatment in the
Eintrag öffnen